Advagene Biopharma Co., Ltd.

6709

TW0006709009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-05 pm EDT			5-day change	1st Jan Change
26.4 ^TWD	-2.04%		+6.67%	+3.94%

Apr. 11	Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Advagene Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Advagene Biopharma Co., Ltd. has filed an IPO.

September 20, 2018 at 12:00 am EDT

Advagene Biopharma Co., Ltd. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: TWD 25

Latest news about Advagene Biopharma Co., Ltd.

Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 11	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-09	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-13	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-21	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-12	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-07	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-11	CI
Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-08	CI
Advagene Biopharma Co., Ltd. has completed an IPO.	18-11-28	CI
Advagene Biopharma Co., Ltd. has filed an IPO.	18-09-20	CI

Chart Advagene Biopharma Co., Ltd.

Duration

Period

More charts

Advagene Biopharma Co., Ltd. is a Taiwan-based company mainly enagegd in the research and development of new drug products through its detoxified LT adjuvant technology platform. The products developed by the Company include nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy) and other vaccines. The detoxified LT adjuvant is genetically engineered to detoxify the heat-labile LT protein (or Escherichia coli heat-labile enterotoxin protein) produced by Escherichia coli.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADVAGENE BIOPHARMA CO., LTD.	+3.94%	44.56M
MODERNA, INC.	+22.81%	47.9B
LONZA GROUP AG	+46.56%	41.42B
IQVIA HOLDINGS INC.	-1.88%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+11.33%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.27B
BIO-TECHNE CORPORATION	-1.43%	12.15B
MEDPACE HOLDINGS, INC.	+30.73%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	11.99B

Other Biotechnology & Medical Research